FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308376189> ?p ?o ?g. }

• W4308376189 abstract "<h3>Background</h3> Inhibitory sialic acid-binding immunoglobulin-type lectins (Siglecs) are a subset of the Siglec family of cell surface receptors expressed predominantly on myeloid cells that potentiate immune suppression. Tumors increase the expression of sialic acid glycans and co-opt the immunosuppressive effects of Siglecs, driving tumor resident immune cells toward a cancer permissive phenotype. Disrupting Siglec-sialic acid signaling could confer a therapeutic benefit in cancer, particularly those cancers with high levels of myeloid derived suppressor cells (MDSCs). To accomplish this, we designed AL009, an engineered Siglec Fc fusion molecule that acts as a sialic acid trap and a multi-Siglec inhibitor, repolarizing suppressive myeloid cells and activating an anti-cancer response. The safety, tolerability, and efficacy of AL009 in patients with solid tumors will be evaluated in an upcoming Phase 1 study. Here we present data that help to refine disease selection for the Phase 1 study and efforts in testing potential predictive biomarkers for clinical use. <h3>Methods</h3> Tissue microarrays from patients with various solid tumors were analyzed by immunohistochemistry (IHC). Markers detected included CD163, CD68<i>,</i> and a representative Siglec for multi-Siglec expression. IHC scoring methodology was prespecified focusing on proportion of cells expressing each of the above markers. Scoring was on a 4-point scale and based upon the number of cells stained with the marker of interest in reasonable proximity to the tumor (tissue without tumor was not scored). <h3>Results</h3> Tumor profiling by IHC identified squamous cell lung cancer, colorectal cancer, ovarian cancer, kidney cancer as indications rich in MDSCs marked by high levels of CD163, CD68, and Siglec expression. These cancer indications may be particularly responsive to AL009. The use of PD-L1 expression data from The Cancer Genome Atlas for these various cancer indications provides further guidance on potential effective combination therapies coupled with AL009. <h3>Conclusions</h3> We employed an IHC panel that marks CD163, CD68, and Siglecs to identify cancer indications rich in MDSCs. As AL009’s mechanism of action is to disrupt the Siglec-sialic acid signaling of MDSCs, we believe that patients with these particular cancers will be most likely to respond to AL009 treatment. This IHC panel will be utilized to retrospectively explore Siglecs, CD163, and CD68 as predictive biomarkers in an upcoming Phase 1 study. <h3>Ethics Approval</h3> The human tissue microarrays were procured from a commercial vendor that collect human samples with the following ethical considerations: informed donor consent, IRB/EC approval, fully anonymized, and compliant with current US (HIPAA) International and EU regulations." @default.
• W4308376189 created "2022-11-11" @default.
• W4308376189 creator A5030455212 @default.
• W4308376189 creator A5032376111 @default.
• W4308376189 creator A5065367500 @default.
• W4308376189 creator A5072412399 @default.
• W4308376189 creator A5079486640 @default.
• W4308376189 date "2022-11-01" @default.
• W4308376189 modified "2023-09-25" @default.
• W4308376189 title "114 Characterization of suppressive myeloid cells in solid tumors to refine disease selection in a Phase 1 study of the multi-Siglec inhibitor AL009" @default.
• W4308376189 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0114" @default.
• W4308376189 hasPublicationYear "2022" @default.
• W4308376189 type Work @default.
• W4308376189 citedByCount "0" @default.
• W4308376189 crossrefType "proceedings-article" @default.
• W4308376189 hasAuthorship W4308376189A5030455212 @default.
• W4308376189 hasAuthorship W4308376189A5032376111 @default.
• W4308376189 hasAuthorship W4308376189A5065367500 @default.
• W4308376189 hasAuthorship W4308376189A5072412399 @default.
• W4308376189 hasAuthorship W4308376189A5079486640 @default.
• W4308376189 hasBestOaLocation W43083761891 @default.
• W4308376189 hasConcept C121608353 @default.
• W4308376189 hasConcept C126322002 @default.
• W4308376189 hasConcept C203014093 @default.
• W4308376189 hasConcept C204232928 @default.
• W4308376189 hasConcept C2778017598 @default.
• W4308376189 hasConcept C2779282312 @default.
• W4308376189 hasConcept C2780115458 @default.
• W4308376189 hasConcept C502942594 @default.
• W4308376189 hasConcept C54355233 @default.
• W4308376189 hasConcept C71924100 @default.
• W4308376189 hasConcept C86803240 @default.
• W4308376189 hasConcept C8891405 @default.
• W4308376189 hasConcept C96232424 @default.
• W4308376189 hasConceptScore W4308376189C121608353 @default.
• W4308376189 hasConceptScore W4308376189C126322002 @default.
• W4308376189 hasConceptScore W4308376189C203014093 @default.
• W4308376189 hasConceptScore W4308376189C204232928 @default.
• W4308376189 hasConceptScore W4308376189C2778017598 @default.
• W4308376189 hasConceptScore W4308376189C2779282312 @default.
• W4308376189 hasConceptScore W4308376189C2780115458 @default.
• W4308376189 hasConceptScore W4308376189C502942594 @default.
• W4308376189 hasConceptScore W4308376189C54355233 @default.
• W4308376189 hasConceptScore W4308376189C71924100 @default.
• W4308376189 hasConceptScore W4308376189C86803240 @default.
• W4308376189 hasConceptScore W4308376189C8891405 @default.
• W4308376189 hasConceptScore W4308376189C96232424 @default.
• W4308376189 hasLocation W43083761891 @default.
• W4308376189 hasOpenAccess W4308376189 @default.
• W4308376189 hasPrimaryLocation W43083761891 @default.
• W4308376189 hasRelatedWork W2339808165 @default.
• W4308376189 hasRelatedWork W2344637265 @default.
• W4308376189 hasRelatedWork W2974647127 @default.
• W4308376189 hasRelatedWork W3049178086 @default.
• W4308376189 hasRelatedWork W3126055100 @default.
• W4308376189 hasRelatedWork W3189892794 @default.
• W4308376189 hasRelatedWork W4283731173 @default.
• W4308376189 hasRelatedWork W4291367166 @default.
• W4308376189 hasRelatedWork W4308359949 @default.
• W4308376189 hasRelatedWork W4360983034 @default.
• W4308376189 isParatext "false" @default.
• W4308376189 isRetracted "false" @default.
• W4308376189 workType "article" @default.